US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Birth Control

1,068.43

-77.2784-6.74%

Number of Gainers:- -

Number of Losers:6

Number of Flat:- -

PE:- -

High:1,127.41

Open:1,127.41

Low:1,033.74

Close:1,145.71

Loading ...

Compass Therapeutics And 2 More Compelling Penny Stocks

Simply Wall St.

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

Teva Pharmaceuticals : UBS Cuts Target Price to $24 From $27

THOMSON REUTERS

BRIEF-Daré Bioscience Reports Full Year 2024 Financial Results

DarÉ Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

THOMSON REUTERS

Dare Bioscience Inc - DarÉ Expects to Start Recording Revenue and Cash Flow in Q4

THOMSON REUTERS

Press Release: Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Teva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749

MT Newswires Live

Teva announces presentation of survey study on TEV-‘749

Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says

MT Newswires Live

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Calendar of U.S. Earnings Expected in the Week Ahead

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Teva Releases Q1 2025 Aide Memoire

THOMSON REUTERS

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

THOMSON REUTERS

Femasys Inc. FY EPS USD -0.85

THOMSON REUTERS

Press Release: Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Evofem announces license and supply agreement with Windtree Therapeutics

BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics

Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":1068.4283,"timestamp":1743796799999,"preClose":1145.7068,"halted":0,"volume":24335913,"delay":0,"changeRate":-0.06745,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-77.278442,"latestTime":"04-04 16:00:00 EDT","open":1127.4084,"high":1127.4084,"low":1033.744,"amount":264788468.424177,"amplitude":0.081753,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.454895,"peRate":-10.345624,"turnoverRate":0.014792,"increases":0,"decrements":6,"flats":0,"marketCap":17417463268,"floatMarketCap":17293913240},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":1127.4084,"amplitude":0.081753,"preClose":1145.7068,"low":1033.744,"pbRate":"3.454895","latestPrice":1068.4283,"volume":24335913,"delay":0,"open":1127.4084,"prevYearClose":1682.2216,"prevWeekClose":1164.1865,"prevMonthClose":1184.288,"prevQuarterClose":1184.288,"fiveDayClose":1164.1865,"twentyDayClose":1184.9766,"sixtyDayClose":1649.4604,"secType":"PLATE","market":"US","turnoverRate":0.014792,"peRate":-10.345624,"marketCap":17417463268,"floatMarketCap":17293913240,"timestamp":1743796799999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":0,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524546189","title":"Compass Therapeutics And 2 More Compelling Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2524546189","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524546189?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:05","pubTimestamp":1743591916,"startTime":"0","endTime":"0","summary":"As the U.S. markets navigate a period of volatility, with the S&P 500 and Nasdaq recently closing higher despite economic uncertainties, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or emerging companies, continue to capture interest due to their affordability and growth potential. While the term may seem outdated, these stocks can offer significant value when backed by strong financials and clear growth strategies. In this article, we explore three compelling penny stocks that stand out for their financial strength and long-term prospects.Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology and other diseases, with a market cap of $262.74 million.Explore Compass Therapeutics' analyst forecasts in our growth report.Overview: Microvast Holdings, Inc. specializes in battery technologies for electric vehicles and energy stor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/compass-therapeutics-2-more-compelling-110516191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MVSTW","BABB","BK4509","BK4023","ARDS","BK4021","SB","BK4505","BK4139","BK4209","TUYA","LENZ","BK4526","BTC","CMPX","VERU","BK4007","BK4563","BK4183","BK4557","BK4584","MVST","BK4179","TTI"],"gpt_icon":0},{"id":"2524550466","title":"Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524550466","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524550466?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:59","pubTimestamp":1743591540,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April  02, 2025  (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune disea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/02/3054090/0/en/Generation-Bio-to-Present-at-the-Needham-24th-Annual-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GBIO","BK4584","HCSG","BK4139","BK4137"],"gpt_icon":0},{"id":"2524157551","title":"Teva Pharmaceuticals : UBS Cuts Target Price to $24 From $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2524157551","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524157551?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:03","pubTimestamp":1743494620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nAZN3N4D62:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEVA","BK4559","BK4596","BK4584","BK4566","BK4585","BK4588","BK4007","BK4557"],"gpt_icon":0},{"id":"2524798972","title":"BRIEF-Daré Bioscience Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524798972","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524798972?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:30","pubTimestamp":1743453024,"startTime":"0","endTime":"0","summary":"BRIEF-Daré Bioscience Reports Full Year 2024 Financial Results March 31 (Reuters) - Dare Bioscience Inc DARE.O:DAR BIOSCIENCE REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATEDARE B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA250XWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4007","BK4584"],"gpt_icon":0},{"id":"2524974392","title":"DarÉ Bioscience Reports Full Year 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524974392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524974392?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:01","pubTimestamp":1743451261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA250XWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4584","DARE"],"gpt_icon":0},{"id":"2524366974","title":"Dare Bioscience Inc - DarÉ Expects to Start Recording Revenue and Cash Flow in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2524366974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524366974?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:01","pubTimestamp":1743451261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA250XWR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4007","BK4584"],"gpt_icon":0},{"id":"2524743119","title":"Press Release: Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524743119","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524743119?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:01","pubTimestamp":1743451260,"startTime":"0","endTime":"0","summary":"With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year. -- Enables women to access a solution that they want and need. -- Creates an opportunity to accelerate revenue generation from this. Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Daré proprietary formulations to market as soon as practicable. \"Healthcare providers and women are seeking a formulation of sildenafil that they can trust. Based on the study published in 2024 I am very excited about the availability of Daré's Sildenafil Cream formulation as an 'on demand' solution for women,\" stated Dr. Sheryl Kingsberg, Division Chief of Behavioral Medicine, Department of OBGYN, University Hospitals Cleveland Medical Center, Ohio, and Past Presid","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4022","BK4007","BK4584","R","BK4232"],"gpt_icon":0},{"id":"2524973911","title":"Teva Says Schizophrenia Trial Survey Results Show Patient Satisfaction With TEV-'749","url":"https://stock-news.laohu8.com/highlight/detail?id=2524973911","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524973911?lang=en_us&edition=fundamental","pubTime":"2025-04-01 01:55","pubTimestamp":1743443736,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  US affiliate Teva Pharmaceuticals said Monday that an attitudes and experiences survey in connection with a schizophrenia trial showed patient and health care professional satisfaction with TEV-'749 or olanzapine as a once-monthly subcutaneous long-acting injectable.The company said over 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about the investigational treatment, which was evaluated in the phase 3 subcutaneous olanzapine extended-release injection study.The company also said that new data from Uzedy assessed predictors of response in schizophrenia, with efficacy seen across patient demographic and clinical characteristics in the phase 3 trial.Uzedy received approval in the US for the treatment of schizophrenia in adults in 2023, according to the company.Shares of Teva Pharmaceutical Industries were up 2.6% in recent trading.Price: 15.48, Change: +0.40, Percent Change: +2.63","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4557","BK4007","BK4596","BK4588","BK4585","TEVA","BK4566","BK4584","BK4559"],"gpt_icon":0},{"id":"2524978547","title":"Teva announces presentation of survey study on TEV-‘749","url":"https://stock-news.laohu8.com/highlight/detail?id=2524978547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524978547?lang=en_us&edition=fundamental","pubTime":"2025-04-01 01:05","pubTimestamp":1743440744,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of a patient and healthcare professiona...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-presentation-of-survey-study-on-tev-749?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-presentation-of-survey-study-on-tev-749?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","BK4566","TEVA","BK4585","BK4007","BK4584","BK4557","BK4596","BK4588"],"gpt_icon":0},{"id":"2523924601","title":"Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2523924601","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523924601?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:54","pubTimestamp":1743436480,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical's  cost-optimization plan, expected to be announced in May, will likely offer at least about $750m in benefits, which could help offset the company's upcoming generic Revlimid EBITDA loss, UBS said in a note to clients Monday.The investment firm said that, after a post Q4 sell-off, Teva shares are trading at about 5 times 2026 consensus estimates for its EPS \"which makes us believe there is no margin expansion priced-in at these levels.\"However, the company's management is confident it can grow its EBITDA through \"strong topline growth and cost optimization,\" the note said.UBS said the \"Revlimid LOE will have a greater impact than what we previously anticipated,\" however, on Teva's Q1 call it will \"look for detailed cost optimization plan to address this impact.\"UBS reiterated its buy rating on Teva and lowered the company's price target to $24 from $27.Price: 15.37, Change: +0.29, Percent Change: +1.89","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4559","BK4566","TEVA","BK4585","BK4007","BK4584","BK4557","BK4596","BK4588"],"gpt_icon":0},{"id":"2523949670","title":"Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949670","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949670?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:30","pubTimestamp":1743424200,"startTime":"0","endTime":"0","summary":"MIAMI, FL, March  31, 2025  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometaboli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052272/11676/en/Veru-to-Participate-in-Fireside-Chat-at-the-Jones-Healthcare-and-Technology-Innovation-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","HCSG","BK4007","BK4584","BK4183","BK4557","BK4137"],"gpt_icon":0},{"id":"2523915166","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2523915166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523915166?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4524","LU0054578231.USD","PENG","LNZA","BK4023","TTGT","AMC","BK4200","PVLA","UNF","RDUS","FTCI","BW","MSM","LPRO","LW","CUK","FC","DARE","RH","RANI","AYI","OMER","SGML","CAG","BK4007","BK4178","SPWH","NCNO","BK4167","BK4584","BLRX","BHST","LNN","BK4086","PVH","SPIR","PROK","GWH","APOG","LOAR","PRGS","ANGO","CELC","SLP","WPRT","BK4141","REKR","NNOX"],"gpt_icon":0},{"id":"2522757405","title":"Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2522757405","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522757405?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:15","pubTimestamp":1743164100,"startTime":"0","endTime":"0","summary":"Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University. MOUNTAIN VIEW, Calif., March 28, 2025----Aditxt, Inc. , , a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. . The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussion will explore the platform’s role in advancing Pearsanta’s mission to address cancer through early detection and prevention.Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/upcoming-aditxt-weekly-highlight-pearsanta-121500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EVFM","ADTX","BK4007","BK4584","BK4139"],"gpt_icon":0},{"id":"2522772531","title":"Teva Releases Q1 2025 Aide Memoire","url":"https://stock-news.laohu8.com/highlight/detail?id=2522772531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522772531?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:30","pubTimestamp":1743107400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA302XQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEVA","BK4559","BK4596","BK4585","BK4588","BK4566","BK4557","BK4584","BK4007"],"gpt_icon":0},{"id":"2522303541","title":"Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303541?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:00","pubTimestamp":1743080402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA54CYWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","BK4539","BK4082","FEMY"],"gpt_icon":0},{"id":"2522303540","title":"Femasys Inc. FY EPS USD -0.85","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303540","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303540?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:00","pubTimestamp":1743080401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLXF3F0FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FEMY","BK4584","BK4082","BK4539"],"gpt_icon":0},{"id":"2522303915","title":"Press Release: Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303915","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303915?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:00","pubTimestamp":1743080400,"startTime":"0","endTime":"0","summary":"-- Company expands commercial product offering with FemBloc permanent birth control  approval in Europe and signed partnerships for distribution in Spain --. ATLANTA, March 27, 2025  -- Femasys Inc. , a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update.in Europe; FemBloc blended polymer component successfully completed an. expedited G12 Special MDR Audit for Class III devices, and the Notified. Body has recommended for CE mark approval pending the final stages of. -- Announced partnership with CNY Fertility, national conglomerate of 11. -- Announced strategic distribution partnerships for FemBloc in Spain. -- Announced peer-reviewed publication of positive safety and efficacy. -- Announced UK and Israeli regulatory approvals for FemaSeed and two. -- Ann","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4022","R","FEMY","BK4584","BK4232","BK4082"],"gpt_icon":0},{"id":"2522805388","title":"Evofem announces license and supply agreement with Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805388","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805388?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:55","pubTimestamp":1742993732,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (EVFM) announced that it has entered into a License and Supply Agreement with Windtree Therapeutics (WINT), under which Windtree...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4007","WINT","LENZ","BK4139","EVFM"],"gpt_icon":0},{"id":"2522204808","title":"BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522204808","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522204808?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:49","pubTimestamp":1742993391,"startTime":"0","endTime":"0","summary":"BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree TherapeuticsMarch 26 (Reuters) - Evofem Biosciences Inc EVFM.PK:EVOFEM EXPECTS SIGNIFICANT REDUC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","BK4007","BK4584","BK4139","WINT"],"gpt_icon":1},{"id":"2522808543","title":"Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522808543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522808543?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:47","pubTimestamp":1742993244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4139","BK4584","BK4007","WINT"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26}]}}